New hope for tough-to-treat pancreatic cancer
NCT ID NCT07302841
Summary
This study is testing whether adding a new drug called tunlametinib to standard chemotherapy and another targeted drug works better for advanced pancreatic cancer. It's for adults who haven't had any prior cancer treatment. The goal is to see if this combination can shrink tumors and control the disease for longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.